Category: Research Publications

REDLAMP 13: How Are Outcomes Improving for Patients with Transformed Follicular Lymphoma?

The diagnosis for follicular lymphoma that has transformed into diffuse large B-cell lymphoma (DLBCL) has in the past been associated with a poor prognosis for patients. However, in a National LymphoCare Study recently published in Blood, researchers assessed the incidence, prognostic features, and outcomes associated with the transformation of follicular lymphoma in enrolled patients. In this video Dr. John Leonard discusses the findings of the study. Specifically reviewed are new data on outcomes, based on novel approaches and therapies for patients whose follicular lymphoma has transformed.

Previous #REDLAMP entries can be viewed on our Youtube channel.

We encourage you to follow the Lymphoma Program on Twitter, Youtube, and Facebook where we will highlight new videos are about research publications as they are released. We also welcome your feedback, suggestions and questions about this project. If you have other questions about our lymphoma program or clinical trials or would like to see one of our lymphoma specialists, please contact us at 212-746-2919.

Ibrutinib—A New Standard Treatment for Mantle Cell Lymphoma?

In The Lancet, Dr. Peter Martin commented on the results of a recently completed phase 3 trial in Europe that compared ibrutinib to temsirolimus among patients with mantle cell lymphoma. He writes that the results of the study clearly establish, “…ibrutinib as a new standard for treatment of relapsed mantle cell lymphoma.” Dr. Martin’s full comments on the topic can be found in the attached PDF below:

Ibrutinib-a new standard treatment for relapsed mantle cell lymphoma?

A full listing of currently available clinical trials for mantle cell lymphoma can be found on the Joint Clinical Trials website.

REDLAMP 12: Lenalidomide & Rituximab Combo Promising as Initial Treatment for Mantle Cell Lymphoma

Mantle cell lymphoma is a B-cell non-Hodgkin lymphoma that primarily affects the elderly. Approach to initial treatment is highly variable, and decisions are made with consideration of balancing efficacy and toxicity. In this video Dr. Jia Ruan discusses results from a study published in the November 5th issue of the New England Journal of Medicine. The study demonstrated that lenalidomide when taken in combination with rituximab provides an effective treatment option .

Previous #REDLAMP entries can be viewed on our Youtube channel.

We encourage you to follow the Lymphoma Program on Twitter, Youtube, and Facebook where we will highlight new videos are about research publications as they are released. We also welcome your feedback, suggestions and questions about this project. If you have other questions about our lymphoma program or clinical trials or would like to see one of our lymphoma specialists, please contact us at 212-746-2919.